Probing RAS Function with Monobodies.

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS proteins, including KRAS, HRAS, and NRAS, are mutated in approximately 20% of human cancers and act as critical oncogenic drivers.
• While KRAS(G12C) inhibitors show promise, other RAS mutations remain difficult to target with current covalent inhibitor chemistries.
• There is a significant need for alternative strategies to develop broadly effective RAS inhibitors.

Purpose of the Study:

• To explore the potential of Monobody (Mb) technology for developing novel RAS inhibitors.
• To identify vulnerabilities in RAS proteins that can be exploited for therapeutic intervention.
• To describe the methods for isolating RAS-specific Mbs and assessing their inhibitory activity.

Main Methods:

• Utilizing Monobody (Mb) technology to identify novel binding sites and vulnerabilities on RAS proteins.
• Isolating RAS-specific Monobodies through a defined screening process.
• Characterizing the inhibitory activity of the isolated RAS-specific Monobodies.

Main Results:

• Successful isolation of RAS-specific Monobodies.
• Demonstration of the inhibitory potential of these Monobodies against RAS targets.
• Identification of new avenues for targeting previously undruggable RAS mutants.

Conclusions:

• Monobody technology presents a viable alternative approach for developing novel RAS inhibitors.
• This strategy can overcome the limitations of existing therapies targeting specific RAS mutations.
• Further development of Monobody-based therapeutics could lead to broadly efficacious treatments for various RAS-driven cancers.